Your Good Partner in Biology Research

TNFRSF9

TNFRSF9:它是重要的激活型免疫檢查點分子,腫瘤治療未來之星

TNFRSF9(也稱為ILA;4-1BB;CD137;CDw137)屬于腫瘤壞死因子(TNF)受體超家族。TNFRSF9是一種II型膜糖蛋白。TNFRSF9在小鼠和人CD4+和CD8+T細(xì)胞中廣泛表達。人TNFRSF9也在DC、單核細(xì)胞、肝癌細(xì)胞、惡性腫瘤患者的血管中表達。TNFSF9為TNFRSF9的配體,也常見為4-1BBL或CD137L。多項研究表明,TNFRSF9/TNFSF9是一對重要的共刺激分子,在活化細(xì)胞與抗原呈遞細(xì)胞之間傳導(dǎo)雙向信號,在各種癌癥、自身免疫、感染和炎癥疾病中扮演多種角色,介導(dǎo)著復(fù)雜的免疫反應(yīng)。近年來一些TNFRSF9激活型單抗顯示出臨床應(yīng)用潛力。例如全人源化TNFRSF9單抗Urelumab已經(jīng)在人類黑色素瘤、腎癌并以及卵巢癌開展了臨床I期和Ⅱ期試驗,耐受性良好。另一個全人源化TNFRSF9單抗Utomilumab(輝瑞公司)被批準(zhǔn)用于晚期實體瘤和惡性B細(xì)胞白血病I期臨床(NCT01307267)試驗。目前流行的理論認(rèn)為,TNFRSF9激動劑可用于治療主要由CD4+T細(xì)胞介導(dǎo)的癌癥和自身免疫性疾病,而TNFRSF9激動劑可能會使由CD8+T細(xì)胞介導(dǎo)的自身免疫性疾病惡化。

Recombinant Human TNFRSF9 活性蛋白實驗驗證數(shù)據(jù)

High Purity Validated by SDS-PAGE

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Excellent Bioactivity Validated by Functional ELISA

Measured by its binding ability in a functional ELISA. Immobilized TNFRSF9 at 2 μg/ml can bind TNFSF9(CSB-MP023997HU1), the EC50 is 1.011-2.429 ng/mL.


TNFRSF9 Antibodies

TNFRSF9 for Homo sapiens (Human)

TNFRSF9 Proteins

TNFRSF9 Proteins for Mus musculus (Mouse)

TNFRSF9 Proteins for Homo sapiens (Human)

TNFRSF9 ELISA Kit

TNFRSF9 ELISA Kit for Homo sapiens (Human)

TNFRSF9 ELISA Kit for Mus musculus (Mouse)